Clik here to view.
DNA Script Extends Distributorships to Middle East to Expand Access to...
SOUTH SAN FRANCISCO, Calif. & PARIS DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) for DNA on demand, has signed distribution agreements in the Middle East with Gulf Scientific...
View ArticleClik here to view.
CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences
BEIJING & CAMBRIDGE, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization...
View ArticleClik here to view.
Veristat Joins Decentralized Trials ＆ Research Alliance (DTRA) to Improve the...
SOUTHBOROUGH, Mass. Veristat announced that it has joined an alliance of over 120 life sciences and healthcare organizations whose mission is to accelerate the broad adoption of patient-focused,...
View ArticleClik here to view.
Biocytogen to Present Progress of Preclinical and Clinical Assets at...
BEIJING Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) will present at the upcoming BIO-EUROPE conference in Leipzig, Germany on October 24-26 and virtually on November...
View ArticleClik here to view.
Syncell Selects $50,000 Grant Opportunity Winners for Spatial Proteomics
TAIPEI, Taiwan & LOS ALTOS, Calif. Syncell, pioneering innovative tools to accelerate the world’s understanding of proteomics, today announced Melissa Wren, Ph.D., & Dmytro Morderer, Ph.D.,...
View ArticleClik here to view.
Immunis Chairman Dr. Hans Keirstead Visits His Holiness the Dalai Lama
IRVINE, Calif. Immunis, Inc., a private biotech company developing a novel treatment for age and disease-related immune decline, announces that its Chairman, renowned neuroscientist Hans Keirstead,...
View ArticleClik here to view.
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
OSAKA, Japan Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2022 (period ended September 30, 2022), upgrading reported and core forecasts and free...
View ArticleClik here to view.
武田薬品工業：2022年度上期は力強い業績を達成、通期予想を上方修正
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TOKYO：4502/NYSE：TAK）は、本日、2022年度上期の業績を公表しましたのでお知らせします。当社は財務ベースおよびCoreベースの通期予想、フリー・キャッシュ・フローを上方修正し、Core財務指標のCERベース での通期マネジメントガイダンスを維持します。 当社代表取締役社長CEOのクリストフ・ウェバー（Christophe...
View ArticleClik here to view.
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate...
CAMBRIDGE, Mass. & SHANGHAI 2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, and JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology...
View ArticleClik here to view.
Vizgen Announces International Expansion into Asia Pacific and EMEA
CAMBRIDGE, Mass. Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the availability of its MERSCOPE™...
View ArticleClik here to view.
武田发布强劲的2022财年上半年业绩并上调全年预期
日本大阪 (美国商业资讯)–武田(Takeda, TOKYO:4502/NYSE:TAK)今天公布了2022财年上半年（截至2022年9月30日的期间）的财务业绩，上调了本财年的报告和核心预测以及自由现金流展望，并重新确认了按恒定汇率(CER)计算的核心增长的管理层指引。 武田首席执行官Christophe Weber评论道：...
View ArticleClik here to view.
IEEE Open Journal of Engineering in Medicine and Biology Report on New AI...
PISCATAWAY, N.J. IEEE, the world’s largest technical professional organization dedicated to advancing technology for humanity, and the IEEE Engineering in Medicine and Biology Society (EMBS) today...
View ArticleClik here to view.
EdiGene to Present Preliminary Safety and Efficacy Results of an Investigator...
BEIJING & CAMBRIDGE, Mass. EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant...
View ArticleClik here to view.
BeiGene to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in two...
View ArticleClik here to view.
OliX Pharmaceuticals Announces Positive Preclinical Data in NASH Non-human...
SUWON, South Korea OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today that the Company has secured positive effects of OLX702A, an investigational...
View ArticleClik here to view.
EdiGene Biotechnology Moves into New R＆D Center at Waltham, Mass. to Advance...
BEIJING & WALTHAM, Mass. EdiGene, Inc., a global, clinical-stage company focused on translating its gene-editing technologies into transformative genetic medicines for patients with significant...
View ArticleClik here to view.
Lemonex, IVI Exchange MOU on Joint Vaccine Development
SEOUL, South Korea The International Vaccine Institute (IVI) announced on November 10th it signed a memorandum of understanding (MOU) with Lemonex, a company specializing in RNA gene therapy...
View ArticleClik here to view.
Kirin Holdings and Kao Begin Joint Research On The Relationship Between...
TOKYO Kirin Holdings Company, Limited (Kirin Holdings) and Kao Corporation (Kao) will participate in the “Wakayama Health Promotion Study” cohort study*1 led by Wakayama Medical University and...
View ArticleClik here to view.
麒麟控股与花王联合研究内脏脂肪与免疫学的关系
东京 (美国商业资讯)–麒麟控股株式会社（Kirin Holdings Company, Limited，简称“麒麟控股”）和花王株式会社（Kao Corporation，简称“花王”）将从本月起参加由和歌山县立医科大学牵头、由非营利组织健康促进研究中心(HPRC)编制的“和歌山健康促进研究”队列研究*1。麒麟控股和花王将联合开展研究，探究内脏脂肪与免疫系统的主要群体之一浆细胞样树突状细胞*2...
View ArticleClik here to view.
Genome Insight and Kun-hee Lee Child Cancer ＆ Rare Disease Project Team of...
SAN DIEGO Genome Insight, a precision medicine whole genome platform company, and Kun-hee Lee Child Cancer & Rare Disease Project Team of SNUH (Seoul National University Hospital), funded by the...
View Article